184 related articles for article (PubMed ID: 3142676)
41. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients.
Bonilla F; Alvarez-Mon M; Merino F; de la Hera A; Alés JE; España P; Durántez A
Cancer; 1988 Feb; 61(4):629-34. PubMed ID: 3257405
[TBL] [Abstract][Full Text] [Related]
45. Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes.
Papamichail M; Baxevanis CN
J Chemother; 1992 Dec; 4(6):387-93. PubMed ID: 1287141
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
Kruse CA; Mitchell DH; Lillehei KO; Johnson SD; McCleary EL; Moore GE; Waldrop S; Mierau GW
Cancer; 1989 Oct; 64(8):1629-37. PubMed ID: 2790675
[TBL] [Abstract][Full Text] [Related]
47. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity.
Tanio Y; Watanabe M; Osaki T; Tachibana I; Kawase I; Kuritani T; Saito S; Masuno T; Kodama N; Furuse K
Jpn J Cancer Res; 1992 Jul; 83(7):736-45. PubMed ID: 1325431
[TBL] [Abstract][Full Text] [Related]
48. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
49. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
Li D; Zhang X; Song Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
51. Lymphokine-activated killer (LAK) cell phenomenon in cluster headache. "In vitro" activation by recombinant interleukin-2.
Giacovazzo M; Stirparo G; DeStefano L; Martelletti P; Rinaldi-Garaci C
Headache; 1989 Mar; 29(3):177-9. PubMed ID: 2785095
[TBL] [Abstract][Full Text] [Related]
52. Effects of interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma.
Hanagiri T; Yoshino I; Takenoyama M; So T; Fujie H; Imabayashi S; Eifuku R; Yoshimatsu T; Osaki T; Nakanishi R; Ichiyoshi Y; Nagashima A; Nomoto K; Yasumoto K
Jpn J Cancer Res; 1998 Feb; 89(2):192-8. PubMed ID: 9548447
[TBL] [Abstract][Full Text] [Related]
53. Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.
Klimpel GR; Herndon DH; Stein MD
J Clin Immunol; 1988 Jan; 8(1):14-22. PubMed ID: 2966807
[TBL] [Abstract][Full Text] [Related]
54. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
Miescher S; Whiteside TL; Moretta L; von Fliedner V
J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
[TBL] [Abstract][Full Text] [Related]
55. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
Kameda T; Negoro T; Hagiwara M; Koyama M; Matsuzaki N; Saji F; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
[TBL] [Abstract][Full Text] [Related]
56. Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer.
Yano T; Yasumoto K; Nomoto K
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):201-8. PubMed ID: 2784761
[TBL] [Abstract][Full Text] [Related]
57. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
58. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
59. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
Sone S; Utsugi T; Nii A; Ogura T
J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
